BioSante Pharmaceuticals, Inc. (BPAX)
-NasdaqGM | Prev Close: | 1.14 |
|---|
| Open: | N/A |
|---|
| Bid: | 1.10 x 600 |
|---|
| Ask: | 1.21 x 100 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 2.01 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.01 - 3.45 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 180,916 |
|---|
| Market Cap: | 102.18M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.86 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- BIOSANTE PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 21)
- BioSante Pharmaceuticals, Inc. Reports First Quarter Financial ResultsBusiness Wire(Fri, May 10)
- BIOSANTE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Fri, May 10)
- BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Special Meetings of Stockholders to Consider Proposed MergerBusiness Wire(Wed, May 8)
- Huge Potential But Tough Entry For Female Sexual Dysfunction Drugsat Seeking Alpha(Tue, May 7)
- 4 Bio Stocks to Buy Todayat Motley Fool(Wed, May 1)
- Ceregene Reports Data From Parkinson's Disease Phase 2b StudyPR Newswire(Fri, Apr 19)
- BioSante Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc. Announce New Merger AgreementBusiness Wire(Fri, Apr 12)
- BIOSANTE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a MateriaEDGAR Online(Fri, Apr 12)
- Reviving The Blockbuster Potential Of Libigel For Biosante And Antares Pharmaat Seeking Alpha(Mon, Apr 8)
- Antares: A Compelling Long Term Investmentat Seeking Alpha(Thu, Mar 21)
- BioSante Pharmaceuticals, Inc. Sends Letter Urging Stockholders to Vote “FOR” Proposed Merger with ANI Pharmaceuticals, Inc.Business Wire(Tue, Mar 19)
- BIOSANTE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters toEDGAR Online(Fri, Mar 15)
- BioSante Pharmaceuticals Announces Adjournment of Its Stockholders Meeting Until April 12, 2013Business Wire(Fri, Mar 15)
- Ceregene And Alzheimer's Disease Cooperative Study Group Complete Enrollment Of CERE-110 Phase 2 TrialPR Newswire(Wed, Mar 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 43.82 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
BioSante Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development of products for female sexual health, menopause, contraception, and male hypogonadism.
View More 
0.52%